SKYER, Inc.

For the past 100 years, the world's population has increased by 1 billion every 13 years. As the population grows, an ecosystem has been changed. The traditional buffer zones that separate humans from animals or from the pathogens that they harbor are notably reduced. And inevitably, the frequency and prevalence of these infectious diseases, defined as ‘zoonosis’, have increased. The most effective way to minimize damages from zoonotic diseases is to detect them earlier.

Born in 2010, SKYER develops and produces high-quality and highly efficient antigen-antibody reaction test kits that have shown consistent sensitivity, specificity, and accuracy. And we will continue our effort to make faster and more accurate test kits by integrating advanced materials and technologies into our system.

We believe rapid tests (also known as lateral flow assays - LFAs - or immunochromatographic strip tests - ICTs), especially in the Point-of-Care Test (POCT), are crucial for managing zoonotic pandemics with the lowest cost.

SKYER pursues creative ideas, open-mindedness, infinite opportunities, and diversity to create a world where humans and nature coexist more safely.